** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7
** Stock on track for its second consecutive session of gains, if trend holds
** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration (FDA)
** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren
** NNZ-2591 used for treatment of any traumatic brain injury
** Stock has risen 11.6% so far this year, as of 0054 GMT
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.